Online first
Original Article
Published online: 2024-11-20
Differential statin intensity and outcomes in patients following myocardial infarction with very low low-density lipoprotein cholesterol
1
, 12, 12, 12, 12, 12, 3, 12, 12
, 12, 12, 12, 12, 12, 3, 12, 12
DOI: 10.5603/cj.99136
Pubmed: 39564956
Abstract
Background: Despite increasing evidence on the benefits of statin therapy for acute myocardial infarction (AMI), differential outcomes in accordance with statin intensity have not been evaluated in patients with AMI and low-density lipoprotein cholesterol (LDL-C) levels < 55 mg/dL. Therefore, this study aimed to compare the clinical outcomes of high- and moderate-intensity statin therapy in this population.
Methods: A total of 752 participants with AMI and LDL-C levels < 55 mg/dL from a Korean nationwide multicenter observational cohort (2016–2020) were included and categorized into two groups: high-intensity statin group (n = 384) and moderate-intensity statin group (n = 368). The primary outcome was 1-year major adverse cardiac and cerebrovascular events (MACCEs). Propensity score matching (PSM) and Cox models were used to determine whether statin intensity independently influenced the primary outcome.
Results: Compared to the moderate-intensity statin group, the high-intensity statin group had a comparable risk of MACCE in all Cox models and PSM-adjusted analyses. The cumulative incidence of MACCE was comparable between the two groups.
Conclusions: Statin intensity appeared to have no significant impact on clinical outcomes in AMI patients with LDL-C levels < 55 mg/dL. These results underscore the need for further investigations aimed at refining treatment strategies for this specific patient cohort, potentially reducing treatment-related burdens without compromising clinical effectiveness.
Keywords: comparative studyLDL cholesterolmyocardial infarctionstatinstreatment outcome
References
- Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020; 41(24): 2313–2330.
- Shapiro MD, Bhatt DL. “Cholesterol-years” for ASCVD risk prediction and treatment. J Am Coll Cardiol. 2020; 76(13): 1517–1520.
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459–2472.
- Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(3): 267–315.
- Grundy SM, Stone NJ, Bailey AL, et al. Aideline on the management of blood cholesterol: executive summary: a reHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guport of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139: e1046–e1081.
- Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42(14): 1289–1367.
- Shapiro MD, Fazio S. From lipids to inflammation: new approaches to reducing atherosclerotic risk. Circ Res. 2016; 118(4): 732–749.
- Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670–1681.
- Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
- Jeong HS, Hong SJ. Benefit of early statin therapy in acute myocardial infarction in korea. Korean Circ J. 2019; 49(5): 434–436.
- Lee KiH, Jeong MHo, Kim HaMi, et al. Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2011; 58(16): 1664–1671.
- Piao ZH, Jin Li, Kim JuH, et al. Benefits of statin therapy in patients with acute myocardial infarction with serum low-density lipoprotein cholesterol ≤ 50 mg/dL. Am J Cardiol. 2017; 120(2): 174–180.
- Kim MC, Ahn Y, Cho JY, et al. Benefit of early statin initiation within 48 hours after admission in statin-naïve patients with acute myocardial infarction undergoing percutaneous coronary intervention. Korean Circ J. 2019; 49(5): 419–433.
- Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017; 120(1): 229–243.
- Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005; 46(10): 1855–1862.
- Oh S, Jeong MHo, Cho KH, et al. Outcomes of nonagenarians with acute myocardial infarction with or without coronary intervention. J Clin Med. 2022; 11(6): 1593.
- Lyu YS, Oh S, Kim JH, et al. Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus. Cardiovasc Diabetol. 2023; 22(1): 185.
- Stone GW, Brodie BR, Griffin JJ, et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary angioplasty in myocardial infarction stent pilot trial investigators. J Am Coll Cardiol. 1998; 31(1): 23–30.
- Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation. 1990; 82(4): 1193–1202.
- Kim MH, Yuan SL, Lee KM, et al. Investigators for KAMIR. Clinical outcomes of calcium-channel blocker vs beta-blocker: from the korean acute myocardial infarction registry. JACC Asia. 2023; 3(3): 446–454.
- Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37(39): 2999–3058.
- Zhang J, Li Q, Wu Y, et al. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer. Cell Commun Signal. 2019; 17(1): 15.
- Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell. 2015; 6(4): 254–264.
- Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971; 74(1): 1–12.
- Iso H, Jacobs DR, Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989; 320(14): 904–910.
- Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham study. JAMA. 1971; 215(10): 1617–1625.
- Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45: 89–118.
- Hashemi M, Hoshyar R, Ande SR, et al. Mevalonate cascade and its regulation in cholesterol metabolism in different tissues in health and disease. Curr Mol Pharmacol. 2017; 10(1): 13–26.
- Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493): 1267–1278.
- Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021; 325: 99–109.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.
- Leeper NJ, Ardehali R, deGoma EM, et al. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation. 2007; 116(6): 613–618.
- Rodriguez F, Maron DJ, Knowles JW, et al. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017; 2(1): 47–54.
- Yu S, Jin J, Chen Z, et al. High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. Lipids Health Dis. 2020; 19(1): 194.
- Cho KH, Jeong MHo, Park KW, et al. Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice: ≥ 50% reduction from baseline versus < 70 mg/dL. Int J Cardiol. 2015; 187: 478–485.
- Kim BK, Hong SJ, Lee YJ, et al. RACING investigators. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022; 400(10349): 380–390.
- Schwartz GG, Gabriel Steg P, Bhatt DL, et al. Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol: a propensity score-matched analysis of the ODYSSEY OUTCOMES trial. Circulation. 2021; 143(11): 1109–1122.
- Sim DS, Jeong MHo, Kim HS, et al. Intensity of statin treatment in Korean patients with acute myocardial infarction and very low LDL cholesterol. J Lipid Atheroscler. 2019; 8(2): 208–220.
- Ahn JHo, Ahn Y, Jeong MHo, et al. Optimal low-density lipoprotein cholesterol target level in Korean acute myocardial infarction patients (< 70 mg/dL vs. < 55 mg/dL): Based on Korea acute myocardial infarction registry-National Institute of Health. Int J Cardiol. 2022; 351: 15–22.
- Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: canadian consensus working group update (2016). Can J Cardiol. 2016; 32(7 Suppl): S35–S65.
- Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020; 76(13): 1507–1516.
- Zhang Y, Pletcher MJ, Vittinghoff E, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. JAMA Cardiol. 2021; 6(12): 1406–1413.
